Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.73 per share a year ago.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q4 2024 earnings on Feb 28, 2025. The consensus estimate for Q4 2024 revenue is $198.35 million, and the earnings are expected to ...

Penn State football has gone all-in this offseason, positioning the Nittany Lions as one of the favorites to win the national title — and athletic director Pat Kraft is a big reason why.

Spring Training is in full swing right now and manager Pat Murphy revealed how the team is viewing Canha as he competes for a role with the organization, as shared by the Milwaukee Journal ...

Starting on Thursday, those on-field drills are televised for all to see. But ESPN's Pat McAfee doesn't want you to look past what takes place on Wednesday, as he so kindly reminded Adam Schefter.

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other oversold pharma stocks to buy according to analysts. On February 20 ...